Biocardia establishes new manufacturing facility to enable its cell therapy product candidates

Facility being built out to support cardiamp cell therapy systems, allogeneic nk1r+ msc and biotherapeutic delivery device manufacturing for clinical trials of multiple programs and early commercial activities facility being built out to support cardiamp cell therapy systems, allogeneic nk1r+ msc and biotherapeutic delivery device manufacturing for clinical trials of multiple programs and early commercial activities
BCDA Ratings Summary
BCDA Quant Ranking